Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy

被引：0

作者：

Stitt, Gideon ^{[1
,2
]}

Morris, Jennifer ^{[2
]}

Schmees, Lindsay ^{[2
]}

Angelo, Joseph ^{[3
]}

Arikan, Ayse Akcan ^{[3
,4
]}

机构：

[1] Childrens Hosp Philadelphia, Dept Pharm Serv, Philadelphia, PA 19104 USA

[2] Texas Childrens Hosp, Dept Pharm Serv, Houston, TX 77030 USA

[3] Baylor Coll Med, Dept Pediat, Renal Sect, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Pediat, Sect Crit Care Med, Houston, TX 77030 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 04期

关键词：

intensive care units; pediatrics; pharmacodynamics; pharmacokinetics; renal replacement therapy; CEFTAZIDIME;

D O I：

10.1128/AAC.02006-18

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This retrospective study included pediatric intensive care unit patients receiving continuous veno-venous hemodiafiltration (CVVHDF) being treated with cefepime. The free drug concentration above one time the MIC (fT>1xMIC) and four times a presumed MIC (fT>4xMIC) of 8 mu g/ml were calculated. Four patients received doses ranging from 48 to 64 mg/kg of body weight every 6 to 12 h. Three patients achieved 100% fT>1xMIC, with the fourth patient achieving 98% fT>1xMIC. Therapeutic drug monitoring should be considered for critically ill patients receiving cefepime on CVVHDF.

引用

页数：5

共 20 条

[1] Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia [J].

Aitken, Samuel L. ;

Altshuler, Jerry ;

Guervil, David J. ;

Hirsch, Elizabeth B. ;

Ostrosky-Zeichner, Luis L. ;

Ericsson, Charles D. ;

Tam, Vincent H. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (05) :541-544

[2] Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration [J].

Allaouchiche, B ;

Breilh, D ;

Jaumain, H ;

Gaillard, B ;

Renard, S ;

Saux, MC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2424-2427

[3]

[Anonymous], 2015, M100S25 CLSI

[4] Principles of antibacterial dosing in continuous renal replacement therapy [J].

Choi, Gordon ;

Gomersall, Charles D. ;

Tian, Qi ;

Joynt, Gavin M. ;

Freebairn, Ross ;

Lipman, Jeffrey .

CRITICAL CARE MEDICINE, 2009, 37 (07) :2268-2282

[5] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10

[6] Cefepime and continuous renal replacement therapy (CRRT):: In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients [J].

Isla, A ;

Gascón, AR ;

Maynar, J ;

Arzuaga, A ;

Toral, D ;

Pedraz, JL .

CLINICAL THERAPEUTICS, 2005, 27 (05) :599-608

[7]

Lexi-Comp, 2019, LEX ONL PED NEON LEX

[8] Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients [J].

Malone, RS ;

Fish, DN ;

Abraham, E ;

Teitelbaum, I .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3148-3155

[9] Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections [J].

McKinnon, Peggy S. ;

Paladino, Joseph A. ;

Schentag, Jerome J. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 (04) :345-351

[10] KILLING OF PSEUDOMONAS-AERUGINOSA DURING CONTINUOUS AND INTERMITTENT INFUSION OF CEFTAZIDIME IN AN IN-VITRO PHARMACOKINETIC MODEL [J].

MOUTON, JW ;

DENHOLLANDER, JG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :931-936

← 1 2 →